Article Details
Retrieved on: 2025-02-04 23:12:10
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses RedHill Biopharma's Phase 2 trial to test opaganib's efficacy with darolutamide in treating treatment-resistant metastatic castrate-resistant prostate cancer (mCRPC). It relates to biopharma through its focus on cancer treatment innovations.
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here